Vaxart, Inc. Forms Clinical and Stockholder Engagement Board Committees

What Happened

• Vaxart, Inc. announced on August 21, 2026 that its Board of Directors created two new committees: the Clinical and Regulatory Affairs Committee and the Stockholder Engagement Committee.
• James B. Breitmeyer, M.D., Ph.D., and David Wheadon, M.D. were appointed to the Clinical and Regulatory Affairs Committee, with Dr. Breitmeyer serving as Chair. W. Mark Watson and Steven Lo were appointed to the Stockholder Engagement Committee, with Mr. Watson serving as Interim Chair.
• The company noted a Cooperation Agreement dated July 1, 2026 and said it anticipates appointing a new director in the future who will serve as Chair of the Stockholder Engagement Committee.

Key Details

• Date of filing/event: August 21, 2026 (8-K reporting date).
• Clinical committee members: James B. Breitmeyer, M.D., Ph.D. (Chair) and David Wheadon, M.D. — charged with oversight and advice on the company’s research, clinical, and regulatory programs.
• Stockholder Engagement committee members: W. Mark Watson (Interim Chair) and Steven Lo — tasked with overseeing advancement of relations with stockholders.
• Related agreement: Cooperation Agreement dated July 1, 2026; company expects to add a director who will chair the Stockholder Engagement Committee.

Why It Matters

• The Clinical and Regulatory Affairs Committee centralizes board-level oversight of Vaxart’s research, clinical development, and regulatory strategy—areas that can materially affect product timelines and regulatory outcomes.
• Creating a Stockholder Engagement Committee and signaling an anticipated new director reflects an increased focus on investor relations and governance, likely tied to the referenced Cooperation Agreement.
• The filing contains forward-looking statements about future director appointment and related actions; investors should note these are subject to risks and uncertainties described in Vaxart’s SEC filings.